|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-5.13/-0.02
|
企业价值
11.03M
|
资产负债 |
每股账面净值
-1.35
|
现金流量 |
现金流量率
--
|
损益表 |
收益
3.02M
|
每股收益
0.31
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/15 08:54 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
INVO Bioscience Inc operates a healthcare services fertility company. Assisted Reproductive Technology (ART) marketplace by making fertility care more accessible and inclusive to people. Its commercial strategy is focused on operating fertility-focused clinics, which includes the opening of dedicated INVO Centers offering the INVOcell and IVC procedure (with three centers in North America now operational) and the acquisition of US-based, profitable in vitro fertilization (IVF) clinics. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors. |